Trial Profile
A Non-Interventional Trial of Pegasys/Copegus in HCV Patients for 12 Months
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2017
Price :
$35
*
At a glance
- Drugs Ribavirin (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 06 Aug 2015 New trial record